Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹7,979 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
₹1,628 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Aurobindo Pharma delivered its highest-ever quarterly revenue of INR 7,979 crore in Q3 FY25, driven by robust US base product sales, strong European growth (+23% YoY), and expansion in growth markets (+39% YoY). EBITDA margin stood at 20.4%, with gross margins expanding 130 bps YoY to 58.4%. Management reiterated its FY25 EBITDA margin guidance of 21%-22%, expecting a stronger Q4 driven by increased transient sales and operational efficiencies. Key growth drivers include the ramp-up of the China plant (contributing from FY26), commercialization of the Dayton OSD facility, and progress in biosimilars with positive CHMP opinions for Filgrastim and Pegfilgrastim. However, the injectables business (Eugia) continues to face capacity utilization challenges at ~50%, though management expects a return to normal run-rate from Q4. Risk: Potential pricing erosion and market share loss for generic Revlimid post patent expiry in January 2026.
Colored figures show movement against the previous available record.
Guidance to track
- Management reaffirmed achieving 21%-22% EBITDA margin for FY25, despite Q3 margin of 20.4%, citing stronger Q4 with increased transient sales and operational efficiencies.
- The China OSD plant (2B units capacity) commercialized in November 2024, expected to ramp up and contribute to revenues in FY26, initially supplying Europe.
- The US-based OSD plant at Dayton is expected to be commercialized in FY26, adding capacity for the US market.
- Following positive CHMP opinions, Filgrastim and Pegfilgrastim expected to launch in EU in Q2 FY26, with revenue bookings starting from that quarter.
Risks flagged
- Patent expiry in January 2026 could lead to pricing erosion and market share loss; management acknowledged uncertainty but plans to continue supply post-expiry.
- Capacity utilization at Eugia remains at 50% due to supply challenges; any further delays in returning to normal run-rate could impact US injectable revenue.
- Omalizumab and ophthalmic product trials are delayed; ophthalmic recruitment only 50% and expected to complete in H2 2026, pushing back potential launches.
- Potential US tariffs on pharmaceutical imports could impact margins; management believes existing US manufacturing footprint provides mitigation.
Key quotes
- We have achieved our highest-ever quarterly revenues, reaching INR 7,979 crores, with a remarkable growth both year-on-year and quarter-on-quarter.
- We are on track to achieve our EBITDA margin of 21%-22% for FY25. The next quarter is expected to be stronger, driven by increased transient sales, execution of strategic initiatives, and improved operational efficiencies.
- I expect this quarter onwards, we should go back to the previous levels, and I don't expect any further decline happening from here on.
Research modules